
TG THERAPEUTICS, INC. — Investor Relations & Filings
TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| FORM 8-K | 2026-05-27 | English | |
| 8-K - TG THERAPEUTICS, INC. (0001001316) (Filer) | 2026-05-06 | English | |
| 8-K - TG THERAPEUTICS, INC. (0001001316) (Filer) | 2026-03-20 | English | |
| 10-K - TG THERAPEUTICS, INC. (0001001316) (Filer) | 2026-02-27 | English | |
| 8-K - TG THERAPEUTICS, INC. (0001001316) (Filer) | 2026-02-26 | English | |
| 4 Filing | 2026-01-29 | English |
Browse filings by year
25 years- 2026 9 filings
- 2025 36 filings
- 2024 48 filings
- 2023 31 filings
- 2022 30 filings
- 2021 32 filings
- 2020 49 filings
- 2019 44 filings
- 2018 43 filings
- 2017 46 filings
- 2016 33 filings
- 2015 47 filings
- 2014 43 filings
- 2013 53 filings
- 2012 47 filings
- 2011 24 filings
- 2010 37 filings
- 2009 36 filings
- 2008 47 filings
- 2007 44 filings
- 2006 30 filings
- 2005 96 filings
- 2004 47 filings
- 2003 36 filings
- 2002 23 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 47845215 | FORM 8-K | 2026-05-27 | English | ||
| 41814189 | 8-K - TG THERAPEUTICS, INC. (0001001316) (Filer) | 2026-05-06 | English | ||
| 33002325 | 8-K - TG THERAPEUTICS, INC. (0001001316) (Filer) | 2026-03-20 | English | ||
| 32885039 | 10-K - TG THERAPEUTICS, INC. (0001001316) (Filer) | 2026-02-27 | English | ||
| 32885038 | 8-K - TG THERAPEUTICS, INC. (0001001316) (Filer) | 2026-02-26 | English | ||
| 26134837 | 4 Filing | 2026-01-29 | English | ||
| 26134841 | 8-K Filing | 2026-01-13 | English | ||
| 26134839 | 4 Filing | 2026-01-09 | English | ||
| 26134836 | 4 Filing | 2026-01-09 | English | ||
|
2025
6 filings
| |||||
| 10629396 | FORM 4 | 2025-11-25 | English | ||
| 10629397 | Regulatory Filings 2025 | 2025-11-24 | English | ||
| 10629398 | FORM 4 | 2025-11-07 | English | ||
| 10629401 | FORM 10-Q | 2025-11-05 | English | ||
| 10629402 | FORM 8-K | 2025-11-03 | English | ||
| 10629404 | FORM 4 | 2025-09-12 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
TG THERAPEUTICS, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31066/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31066 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31066 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31066 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31066}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for TG THERAPEUTICS, INC. (id: 31066)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.